drugset / Trial / NCT03918850

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes. The primary hypothesis is that the BUP-XR group will not have greater illicit opioid use than the BUP-SL group during pregnancy (non-inferiority).

Timeline

Start
2020-07-21
Primary completion
2025-01-31
Completion
2025-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 16 mg Other
Comparator Buprenorphine Other / unclassified 24 mg Subcutaneous
Comparator Buprenorphine Other / unclassified 96 mg Subcutaneous